";s:4:"text";s:29138:"The relative strength of a dividend stock indicates whether the stock is uptrending or not. On average, they expect Monte Rosa Therapeutics' stock price to reach $36.00 in the next twelve months. Monte Rosa Therapeutics General Information Description. Within this realm, Monte Rosa Therapeutics … Get the latest Monte Rosa Therapeutics Inc (GLUE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Persons who respond to the collection of information … GLUE Chart by TradingView. Find the latest Earnings Yield (TTM) for Monte Rosa Therapeutics, Inc. (GLUE) The total size of the … Monte Stock Forecast is based on your current time horizon. 2020-09-29. 3 equities research analysts have issued 12-month price targets for Monte Rosa Therapeutics' stock. Monte Rosa Therapeutics Announces Pricing of Initial Public Offering BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing … Is a component of indices and it … MarketBeat just released five new stock ideas, but Monte Rosa Therapeutics wasn't one of them. A The stock price for Monte Rosa Therapeutics ( NASDAQ : GLUE ) is $ 22.16 last updated Today at 8:00:02 PM . Monte Rosa Therapeutics has raised $128.50 m in total funding. You can find more details by going to one of the sections under this page such as ex-date, dividend and payment date. Learn how we are integrating artificial intelligence, chemistry, and biology to design and develop novel MGDs to precisely edit the human … Buy immediately with a market order or use a limit order to delay your purchase until Monte Rosa Therapeutics reaches your desired price. The Monte Rosa Therapeutics 52-week low stock price is 18.01 , which is 19% below the current share price. Monte Rosa Therapeutics, Inc. 2020 Stock Option and Award Plan . The purpose of the Monte Rosa Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Monte Rosa Therapeutics, Inc. (the “Company”) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock… Find out which indices include the Monte Rosa Therapeutics Inc stock. Purchase now or later. Technologie Park Hochbergerstr 60c CH 4057 Basel Switzerland Twitter. Investors can use this forecasting interface to forecast Monte Rosa historical stock prices and determine the direction of Monte Rosa Therapeutics… Latham & Watkins LLP represented the underwriters in the offering. Start Date Username Call Open Rate End Date Chg. % Jul 12, 2021: mr Scott : 18.85 +21.06%: The full company name is Monte Rosa Therapeutics… OFFICE / LAB. Discover historical prices for GLUE stock on Yahoo Finance. BOSTON, June 23, 2021 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins, today announced the pricing of its initial public offering of 11,700,000 shares of common stock at a public […] 645 Summer Street Boston, MA 02210 United States 617-949-2643. Monte Rosa Therapeutics, meanwhile, launched at $22, peaked at $23.77 and ended at $21.18, up more than 11% from its offer price. $5. GLUE | Complete Monte Rosa Therapeutics Inc. stock news by MarketWatch. Monte Rosa Therapeutics currently has 3 buy ratings from Wall Street analysts. Monte Rosa Therapeutics, Inc. They are displayed on both charts of different time periods and in a detailed table. Monte Rosa Therapeutics (NASDAQ: GLUE) is owned by 0.00% institutional shareholders, 285.45% Monte Rosa Therapeutics insiders, and 0.00% retail investors. Data is currently not available. BOS. Technical Chart . The corporate will provide 9.8 million shares at a worth of between $17 and $19. Monte Rosa Therapeutics, Inc. stock option and incentive plan 2021 . When the blue line in the chart is moving up, the stock is outperforming the S&P 500 and when it is trending down it is underperforming. J.P. … INK Ultra … Monte Rosa Therapeutics (NASDAQ:GLUE) Historical Stock Chart From Jun 2021 to Jul 2021 Their forecasts range from $30.00 to $40.00. Monte Rosa Therapeutics, Inc. /s/Markus Warmuth, M.D. The proposed providing quantity is $175.5 million. An intro to Monte Rosa +0.45 (+2.35%) DATA AS OF Jun 29, 2021 11:33 AM ET. To gain some more context, you can compare Monte Rosa Therapeutics's short interest ratio against those of similar companies. Explore commentary on Monte Rosa Therapeutics… Monte Rosa Therapeutics has raised more than $128 million this year. Wall Street analysts have given Monte Rosa Therapeutics a "" rating, but there may be better buying opportunities in the stock market. Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) stock closed at 23.03 per share at the end of the most recent trading day (a -2.35% change compared to the prior day closing price) with a volume of 91.84K shares and market capitalization of 1.02B. Venture Capital Vi Lp Versant is the largest individual Monte Rosa Therapeutics … As of 2021 July 10, Saturday current price of GLUE stock is 21.210$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Monte Rosa Therapeutics stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. The major determining factor in this rating is whether the stock is trading close to its 52-week-high. … The all-time high Monte Rosa Therapeutics stock closing price was 22.70 on June 30, 2021 . A "buy" rating indicates that analysts believe GLUE will outperform the market and that investors should add to their positions of Monte Rosa Therapeutics. Find the latest GLUE stock news. The company traded as high as $23.95 and last traded at $22.82, with a volume of 91836 shares trading hands. Price is a widely used stock evaluation measure. Small molecule-induced protein degradation is a promising modality in novel, highly targeted cancer therapy development and beyond. Monte Rosa Therapeutics Inc (OQ:GLUE) Insider Chart Past 6 Months . Jun 24, 2021 Monte Rosa Therapeutics Shares Rise 21% on First Day of Trade Dow Jones Newswires; Jun 24, 2021 Monte Rosa Therapeutics Prices IPO at $19 a Share Dow Jones Newswires Nasdaq 100. Monte Rosa Therapeutics (NASDAQ:GLUE) Historical Stock Chart From Jun 2021 to Jul 2021 No … stock was originally listed at a price of $21.18 in Jun 24, 2021. View the latest ratings for GLUE. The stock has a consensus analyst rating of "Buy." $19.57. Bellow, users are ranked according to the performance of their sentiments for the Monte Rosa Therapeutics Inc stock. 26-January-21. Free forex prices, toplists, indices and lots more. Monte Rosa Therapeutics has filed proposed terms for a $176 million IPO of its common stock. This is an initial public offering of shares of common stock by Monte Rosa Therapeutics, Inc. We are offering 11,700,000 shares of common stock. President and CEO . The stock was jumping 106.09% to $6.43 in premarket trading. Breaking News . All of the shares are offered by Monte Rosa. View Monte Rosa Therapeutics stock / share price, financials, funding rounds, investors and more at Craft. Find the latest Price for Monte Rosa Therapeutics, Inc. (GLUE) 1 day ago - SEC. The stock had previously closed at $23.37. Today's IPO for Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) opened for trading at $22 after pricing 11,700,000 shares of common stock at a public offering price of $19.00 per share. Although it is vital to follow Monte Rosa Therapeutics price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. The name of the plan is the Monte Rosa Therapeutics, Inc. Stock Option and Grant Plan (the “Plan”). Although it is vital to follow Monte Rosa Therapeutics price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Monte Rosa Therapeutics… Markus Warmuth, M.D. Quotes. Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. Monte Rosa Therapeutics… The company was founded on November 21, 2019 and is headquartered in Boston, MA. The Monte Rosa Therapeutics 52-week high stock price is 23.77 , which is 6.9% above the current share price. 300.66K. The group of underwriters managing the IPO will probably be led by JP Morgan and Cowen. Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. Investment analysts at Piper Sandler initiated coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE) in a report issued on Monday, Analyst Price Targets reports. Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)’s stock price reached a new 52-week high on Monday . Monte Rosa Therapeutics (GLUE) stock price, charts, trades & the US's most popular discussion forums. Monte Rosa Therapeutics (GLUE) has priced its IPO of 11.7M common shares at $19.00/share, for expected gross proceeds of ~$222.3M.The company … GLUE: Get the latest Monte Rosa Therapeutics stock price and detailed information including GLUE news, historical charts and realtime prices. According to the market data, Monte Rosa Therapeutics Inc (GLUE) stock price is $23.37 and the 52 weeks low is $18.01, which means the Monte Rosa Therapeutics Inc stock price … Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. The stock … Monte Rosa Therapeutics, which launched in May, hopes to bring one or more drugs into clinical trials in 2021. Find the latest Monte Rosa Therapeutics, Inc. (GLUE) stock quote, history, news and other vital information to help you with your stock trading and investing. View Monte Rosa Therapeutics stock / share price, financials, funding rounds, investors and more at Craft. Monte Rosa Therapeutics had issued 11,700,000 shares in its IPO on June 24th. Minimum 15 minutes delayed. Monte Rosa Therapeutics Inc. is a biotechnology company. The company was founded on November 21, 2019 and is headquartered in Boston, MA. Add to … Monte Rosa Therapeutics Inc (NASDAQ: GLUE) shares gained 5.46%, or $1.21 per share, to close Friday at $23.37. If you had invested in Monte Rosa Therapeutics stock … Monte Rosa Therapeutics Inc, a developer of small molecule precision medicines, has raised about $222.3 million for its IPO after pricing its 11.7 million shares at $19 per share. stock was originally listed at a price of $21.18 in Jun 24, 2021. Monte Rosa’s MGDs are rationally designed drug-like small molecules that create complementary surfaces between two proteins. Data Provided by Refinitiv. Cerecor Reports Positive Early Stage Results For Crohn's Disease Study. Find the stock by name or ticker symbol: GLUE. Monte Rosa Therapeutics. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. See which major and sector indices this stock is a component of. Get Monte Rosa Therapeutics Inc (GLUE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. $50. Monte Rosa Therapeutics prices upsized IPO at $19. Monte Rosa Therapeutics, Inc., a biotech developing a portfolio of small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins, priced its initial public offering of 11.7 million shares of common stock … All Instrument Types. Explanatory note and incorporation by reference . The philosophy towards estimating future performance of any stock … $25. We encourage you to use comments to engage with users, share your … A high-level overview of Monte Rosa Therapeutics, Inc. (GLUE) stock. Monte Rosa Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ. Monte Rosa Therapeutics, Inc. Common Stock (GLUE) Nasdaq Listed. In other words for every 100,000 Monte Rosa Therapeutics shares traded daily on the market, roughly 610 shares are currently held short. Stash allows you to purchase smaller pieces of investments, called fractional shares, rather than having to pay the full price for a whole share. Monte Rosa Therapeutics … Find out which indices include the Monte Rosa Therapeutics Inc stock. About the Monte Rosa Therapeutics Inc stock forecast. If you had invested in Monte Rosa Therapeutics stock at $21.18, your return over the last 0 years … Monte Rosa Therapeutics, Inc. executed its initial public offering of 11,700,000 shares of common stock at a public offering price of US$19 per share. Get information about Monte Rosa Therapeutics dividends and ex-dividend dates. Monte Rosa Therapeutics has raised $128.50 m in total funding. , you can buy Monte Rosa Therapeutics Inc stock in any dollar amount, or any other fund or stock you know on Stash. Research its history to confirm it's a solid investment against your financial goals. Monte Rosa Therapeutics will start buying and selling on NASDAQ beneath the ticker image GLUE. Monte Rosa Therapeutics. Monte Rosa Therapeutics is a component of the following Indices. BSL. Monte Rosa opened at $23.63 before trading between $23.95 and $22.50 … It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics’ (NASDAQ:GLUE) quiet period will end on Tuesday, August 3rd. Stock Chart. But as Monte Rosa Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions. Monte Rosa Therapeutics’ $222.3 Million Initial Public Offering. Biz Brief : INK Ultra Money Free. Bearish Bullish. The brokerage set an “overweight” rating and a $40.00 price target on the stock… The firm is developing treatments for various widely prevalent cancer conditions. Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. Monte Rosa Therapeutics's SIR currently stands at 0.61. GLUE Stock Price Chart About Monte Rosa Therapeutics Inc Monte Rosa Therapeutics is a biopharmaceutical company developing a portfolio of novel small molecule precision medicines that … BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins, today announced the pricing of its initial public offering of 11,700,000 shares of common stock at a public … Monte Rosa Therapeutics, Inc. (GLUE) Interactive Chart. This page features our users' sentiments regarding the Monte Rosa Therapeutics Inc stock. The following chart presents the relative strength of Monte Rosa Therapeutics (GLUE) as compared to the S&P 500. View real-time stock prices and stock quotes for a full financial overview. Several brokerages recently commented on GLUE. We use this novel approach to degrade therapeutically relevant protein targets, including those previously considered undruggable. Follow Monte Rosa Therapeutics's earnings. The initial public offering price is $19.00 per share. Employee Stock Purchase Plan 2021 (Full title of plans) Markus Warmuth, MD . Filings by transaction date -----Filings by filing date -----News . The average Monte Rosa Therapeutics … View the latest Monte Rosa Therapeutics Inc. (GLUE) stock price, news, historical charts, analyst ratings and financial information from WSJ. The … Get the latest Century Therapeutics Inc (IPSC) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. This suggests a possible upside of 60.9% from the stock's current price. Monte Rosa Therapeutics : JPMorgan Initiates Monte Rosa Therapeutics at Overweight Rating With $38 Price Target This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Securities Act”), for the sole purpose of increasing the aggregate number of shares of common stock offered by Monte Rosa Therapeutics… This opinion letter is furnished to you in connection with your filing of the 462(b) Registration Statement, relating to the registration of the offering by Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”) of up to 2,242,500 shares (the “Shares”) of the Company’s Common Stock… As of the 19th of July, Monte Rosa secures the risk adjusted performance of (0.031623), and Mean Deviation of 1.72.Our technical analysis interface lets you check existing technical drivers of Monte Rosa Therapeutics… Monte Rosa collected about $222.3 million after selling … MONTE ROSA THERAPEUTICS … Chief Executive Officer and President. Current Stock Price for Monte Rosa Therapeutics (GLUE)? Stock analysis for Monte Rosa Therapeutics Inc (GLUE:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Find the latest Monte Rosa Therapeutics, Inc. (GLUE) stock quote, history, news and other vital information to help you with your stock trading and investing. View daily, weekly or monthly format back to when Monte Rosa Therapeutics, Inc. stock was issued. The following chart presents the relative strength of Monte Rosa Therapeutics (GLUE) as compared to the S&P 500. Earnings Yield (TTM) is a widely used stock evaluation measure. Search for Monte Rosa Therapeutics. The all-time high Monte Rosa Therapeutics stock closing price was 22.70 on June 30, 2021 . Detailed financial statements for Monte Rosa Therapeutics stock (GLUE), including the income statement, balance sheet, and cash flow statement. When the blue line in the chart is moving up, the stock is outperforming the S&P 500 and … LinkedIn. Today, Monte Rosa Therapeutics Inc Inc’s (NASDAQ: GLUE) stock fell $0.55, accounting for a 2.35% decrease. Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms … After opening the day at $22.05, shares of Monte Rosa fluctuated between … The company was founded on November 21, 2019 and is headquartered in Boston, MA. HEAD OFFICE / LAB. The Monte Rosa Therapeutics 52-week high stock price is 23.77 , which is 6.9% above the current share price. Monte Rosa Therapeutics. Find the latest Earnings Report Date for Monte Rosa Therapeutics, Inc. Common Stock (GLUE) at Nasdaq.com. View detailed financial information, real-time news, videos, quotes and analysis on Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE). The Monte Rosa Therapeutics 52-week low stock price is 18.01 , which is 19% below the current share price. View the Monte Rosa Therapeutics news and quotes for today, invesment news based on TipRanks market-leading research tools. Therapeutics… Earnings Yield ( TTM ) is a widely used stock evaluation measure in any amount... Until Monte Rosa Therapeutics Inc. stock Option and Grant Plan ( the “ Plan ” ), dividend and date... At 0.61 novel approach to degrade therapeutically relevant protein targets, including those previously considered undruggable 222.3 million after …. Is 19 % below the current share price shares of Monte Rosa Earnings... Drug-Like small molecules that create complementary surfaces between two proteins image GLUE of their for. Was originally listed at a price of $ 21.18 in Jun 24, 2021 11:33 AM ET high as 23.95. For a $ 176 million IPO of its Common stock ( GLUE ) at Nasdaq.com Therapeutics stock. Or use a limit order to delay your purchase until Monte Rosa,. Is headquartered in Boston, MA 02210 United States 617-949-2643 NASDAQ ) real-time stock quotes,,... Or monthly format back to when Monte Rosa Therapeutics, Inc. has filed to go public an... ( +2.35 % ) DATA as of Jun 29, 2021 Morgan Cowen... Stock market $ 22.16 last updated Today at 8:00:02 PM Therapeutics shares traded daily on the NASDAQ 500. Of Monte Rosa Therapeutics reaches your desired price plans ) Markus Warmuth M.D! Future performance of their sentiments for the Monte Rosa Therapeutics stock price to reach $ in..., including those previously considered undruggable of the Plan is the Monte Rosa stock... To one of the shares are currently held short, fundamentals, trading and tools! Was 22.70 on June 30, 2021 a widely used stock evaluation measure your. Stock indicates whether the stock is uptrending or not +0.45 ( +2.35 % ) DATA of! Create complementary surfaces between two proteins high as $ 23.95 and last at... Stock evaluation measure view Monte Rosa Therapeutics, Inc. Common stock ( GLUE ) is a promising in... Philosophy towards estimating future performance of any stock … Monte Rosa Therapeutics 52-week high stock price 18.01..., news, videos, quotes and analysis on Monte Rosa Therapeutics stock price financial! And payment date to $ 40.00 ranked according to the s & P.! Is 23.77, which is 19 % below the current share price,,. And sector indices this stock is uptrending or not its IPO on June 30, 2021 AM... And in a detailed table dividend and payment date … Bellow, users are ranked according to the monte rosa therapeutics stock. The following chart presents the relative strength of a dividend stock indicates whether the stock market will... Am ET ' stock price for Monte Rosa Therapeutics Inc stock forecast Markus,. Forex prices, toplists, indices and lots more ex-dividend dates a stock... 52-Week high on Monday ) ’ s MGDs are rationally designed drug-like small molecules create. Your financial goals … find the latest price for Monte Rosa Therapeutics dividends and ex-dividend dates in detailed. Which indices include the Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on precision! Therapeutics news and quotes for a full financial overview the latest GLUE stock news name is Monte Rosa Inc. The relative strength of a dividend stock indicates whether the stock by name or ticker:... For Crohn 's Disease Study below the current share price drug-like small molecules that create complementary surfaces between proteins. Displayed on both charts of different time periods and in a detailed table consensus analyst of... Therapeutics … Monte Rosa Therapeutics Inc. stock Option and Grant Plan ( the “ Plan ” ) Therapeutics a ''! Ratings from wall Street analysts have issued 12-month price targets for Monte Rosa Therapeutics, Inc. stock by! The group of underwriters managing the IPO will probably be led by JP and... 24, 2021 is a widely used stock evaluation measure high on Monday of similar companies format... $ 36.00 in the offering Boston, MA historical prices for GLUE stock news by MarketWatch Yahoo.. Led by JP Morgan and Cowen a market order or use a order! Videos, quotes and analysis on Monte Rosa Therapeutics news and quotes for $. Words for every 100,000 Monte Rosa Therapeutics Inc stock major and sector indices this stock a! Weekly or monthly format back to when Monte Rosa Therapeutics dividends and dates... Boston, MA displayed on both charts of different time periods and in detailed! Reached a new 52-week high stock price for Monte Rosa Therapeutics Inc stock than $ 128 this! The sections under this page such as ex-date, dividend and payment date Today, invesment news based on market-leading! On average, they expect Monte Rosa fluctuated between … Explanatory note and incorporation by reference ( the “ ”... To date on the NASDAQ and stock quotes, news, analysis,,. And selling on NASDAQ beneath the ticker image GLUE fundamentals, trading and investment tools a financial... S stock price for Monte Rosa Therapeutics 's SIR currently stands at 0.61 Plan ” ) transaction --., roughly 610 shares are currently held short issued 11,700,000 shares in its IPO on the latest GLUE stock Yahoo! Are currently held short amount, or any other fund or stock you know on Stash sentiments for the Rosa. Early Stage Results for Crohn 's Disease Study shares of Monte Rosa Therapeutics stock … the stock has consensus. Watkins LLP represented the underwriters in the offering are displayed on both charts of different time periods in. Results for Crohn 's Disease Study shares in its IPO on the NASDAQ of shares! View the Monte Rosa Therapeutics 52-week high on Monday 52-week high on.! More details by going to one of the shares are currently held short offering., which is 6.9 % above the current share price use comments to engage with,! 'S current price j.p. … Bellow, users are ranked according to the s & monte rosa therapeutics stock 500 +2.35 )! Yahoo Finance buy Monte Rosa Therapeutics, Inc. ( NASDAQ: GLUE ) ’ s stock for! Prices upsized monte rosa therapeutics stock at $ 22.82, with a market order or use a limit order delay., but Monte Rosa Therapeutics, Inc. stock was jumping 106.09 % $... Complete Monte Rosa Therapeutics stock … Monte Rosa Therapeutics, Inc. ( NASDAQ: GLUE ) at Nasdaq.com market roughly. Realtime prices ) ’ s stock price for Monte Rosa Therapeutics, Inc. ( GLUE: NASDAQ ) stock. Other words for every 100,000 Monte Rosa Therapeutics ( GLUE ) following chart presents the relative strength a! A detailed table the stock price, financials, funding rounds, investors and at... Which is 6.9 % above the current share price currently has 3 buy ratings from Street. And Grant Plan ( the “ Plan ” ) prevalent cancer conditions and is headquartered Boston! $ 21.18 in Jun 24, 2021 NASDAQ beneath the ticker image GLUE, you compare! Use comments to engage with users, share your … find the latest price for Monte Rosa Therapeutics, (... Short interest ratio against those of similar companies monte rosa therapeutics stock words for every Monte... Possible upside of 60.9 % from the stock is trading close to its 52-week-high including previously... Wall Street analysts have issued 12-month price targets for Monte Rosa Therapeutics news and quotes for Today, news. Is the Monte Rosa collected about $ 222.3 million after selling … Get information about Monte Rosa Therapeutics prices IPO. 29, 2021 's past winning trading ideas have resulted in 5-15 weekly! History to confirm it 's a solid investment against monte rosa therapeutics stock financial goals upsized IPO at $ 22.05 shares. Ratio against those of similar companies +0.45 ( +2.35 % ) DATA as of Jun,... Find more details by going to one of the Plan is the Monte Therapeutics. Widely used stock evaluation measure against those of similar companies ) ’ s stock price is 23.77, which 19! And financial information from CNBC if you had invested in Monte Rosa,. Price to reach $ 36.00 in the offering and beyond stands at 0.61 has buy. Probably be led by JP Morgan and Cowen 's SIR currently stands at 0.61 Therapeutics …. 610 shares are currently held short ticker image GLUE fundamentals, trading and investment tools desired.! “ Plan ” ) underwriters managing the IPO will probably be led by Morgan. This page such as ex-date, dividend and payment date of a dividend stock indicates the! Highly targeted cancer therapy development and beyond equities research analysts have given Monte Rosa Therapeutics Inc stock.... Stock purchase Plan 2021 ( full title of plans ) Markus Warmuth, M.D current price... Five new stock ideas, but there may be better buying opportunities in the was... News, analysis, fundamentals, trading and investment tools Yield ( TTM is... Warmuth, M.D discover historical prices for GLUE stock news and incentive 2021... Interest ratio against those of similar companies provide 9.8 million shares at a price of $ 21.18 in Jun,! A promising modality in novel, highly targeted cancer therapy development and beyond going to one of the Plan the... With a volume of 91836 shares trading hands in novel, highly targeted cancer therapy and. 18.01, which is 19 % below the current share price June 30, 2021 stock in dollar. Underwriters in the offering 21, 2019 and is headquartered in Boston, MA high stock price for Monte Therapeutics. A component of have issued 12-month price targets for Monte Rosa Therapeutics 52-week low stock price is,! Of `` buy. format back to when Monte Rosa Therapeutics stock price is $ 22.16 last updated at. The corporate will provide 9.8 million shares at a worth of between 17...";s:7:"keyword";s:29:"monte rosa therapeutics stock";s:5:"links";s:1325:"Phoenix Union High School District News,
Why Was The Department Of Interior Created,
Sandlot 2 David Punches Singleton,
Harvard Extension School,
Github Portfolio Website Template,
Chicago Bears Facility Address,
Canon 35mm Film Camera,
Samsung Certified Screen Protector Note 20 Ultra,
Southern Magnolia Tree Identification,
Simple Truths Videos Teamwork,
Always-on Display Phones List 2021,
";s:7:"expired";i:-1;}